Dermata Therapeutics, Inc. (DRMA) Stock Score, Valuation & Financial Research

Dermata Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DRMA

Dermata Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.13. These figures are a research snapshot, not a buy or sell recommendation.

What Dermata Therapeutics, Inc. does

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Dermata Therapeutics is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and debt financing to fund the research and development of its proprietary product candidates for medical skin diseases and aesthetic applications.

Products and services

  • The company is developing product candidates including XYNGARI (a topical gel for acne) and DMT410 (a botulinum toxin product for hyperhidrosis).

Brands and product families

  • XYNGARI — A product candidate for the treatment of moderate-to-severe acne. Source

Customer types

Dermatologists.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are unnamed. Source

Business relationships and partnerships

  • Revance Therapeutics, Inc. — A clinical trial collaboration agreement to conduct a multi-center Phase 2 clinical trial evaluating the topical application of DMT410. Source

Competitors and product-market comparisons

  • Pharmaceutical and Biotechnology Companies — The company competes with various established pharmaceutical and biotechnology companies developing treatments for acne and other dermatological conditions. Source

Business strengths to evaluate

  • Management experience in dermatology Source

Business risks and research considerations

  • History of operating losses and accumulated deficit Source
  • Dependence on successful clinical trial results and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DRMA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.13
Market capitalization:
4.55M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -8.37M
Free cash flow:
USD -7.76M
Cash:
USD 4.41M
Total debt:
USD 0.00
EPS:
USD -4.39

What stands out

  • Free cash flow is USD -7.76M, negative for the stored period.
  • The balance sheet shows USD 4.41M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.41M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DRMA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DRMA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DRMA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DRMA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DRMA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research DRMA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.